CTI BioPharma Corp. (CTIC: NASDAQ)
$0.37 n/a | n/a%
06/24/16 - 04:00 PM ET
Company Income Statement
Income Statement data is not available for CTIC.
Portfolios with CTIC
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorUnder-$10 Setting Up To Tra...
- User2012 stock
- ContributorCancer Drug Stocks to Trade...
- UserASCO 2010
- Contributor10 Biotech Stocks Facing FD...
Latest CTIC Headlines from TheStreet
- First Week of March 2016 Options Trading For CTI BioPharma (CTIC) 07.21.15 | 12:07 pm
- Insider Trading Alert - ABM, CNBKA And CTIC Traded By Insiders 07.09.15 | 10:07 am
- Interesting CTIC Put And Call Options For August 21st 06.23.15 | 12:06 pm
- Strong On High Relative Volume: Cell Therapeutics (CTIC) 06.15.15 | 10:06 am
- Cell Therapeutics (CTIC) Is Today's Perilous Reversal Stock 06.11.15 | 09:06 am
- Strong On High Volume: Cell Therapeutics (CTIC) 06.01.15 | 10:06 am
- Cell Therapeutics (CTIC) Strong On High Relative Volume Today 05.21.15 | 10:05 am
- First Week of July 17th Options Trading For CTI BioPharma (CTIC) 05.19.15 | 10:05 am
- Short Interest In CTI BioPharma Expands By 10.2% 05.14.15 | 09:05 am
- Interesting CTIC Put And Call Options For December 18th 04.21.15 | 12:04 pm
Press Releases for CTIC
- CTI BioPharma To Report Second Quarter 2015 Financial Results On August 6, 2015 - PR Newswire 07.28.15 | 01:07 am
- CTI BioPharma Appoints Bruce J. Seeley As Executive Vice President And Chief Commercial Officer - PR Newswire 07.27.15 | 01:07 am
- CTI BioPharma To Report First Quarter 2015 Financial Results On May 6, 2015 - PR Newswire 04.23.15 | 01:04 am
- CTI BioPharma And Baxter Announce Phase 3 Data Of Pacritinib In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At ASCO - PR Newswire 04.22.15 | 01:04 am
- CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis - PR Newswire 03.16.15 | 02:03 am
- CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis - PR Newswire 03.09.15 | 07:03 am
- CTI BioPharma To Host Conference Call And Webcast On March 9 - PR Newswire 03.06.15 | 08:03 pm
- CTI BioPharma To Report Fourth Quarter And Full Year 2014 Financial Results On March 12, 2015 - PR Newswire 02.26.15 | 01:02 am
- CTI BioPharma Announces Independent DMC Recommendation To Continue GOG-0212 Phase 3 Study Of OPAXIO™ As Maintenance Therapy In Ovarian Cancer, An NRG Oncology/GOG Study - PR Newswire 02.03.15 | 01:02 am
- CTI BioPharma Announces 2015 Outlook And Recent Drug Portfolio Progress - PR Newswire 01.08.15 | 01:01 am
Partner Headlines for CTIC
- CTI-Baxalta Drug Withdrawn, Removing Potential Incyte Rival - Investor's Business Daily 02.10.16 | 01:02 pm
- CTI BioPharma downgraded to Neutral from Buy at Ladenburg - The Fly 02.10.16 | 09:02 am
- Pacritinib hold an incremental positive for Incyte, says Leerink - The Fly 02.10.16 | 08:02 am
- CTI BioPharma downgraded to Sell from Hold at WallachBeth - The Fly 02.10.16 | 06:02 am
- CTI BioPharma downgraded to Neutral from Overweight at Piper Jaffray - The Fly 02.10.16 | 05:02 am
- CTI BioPharma set for 'transformational' 2016, says Piper Jaffray - The Fly 12.10.15 | 06:12 am
- CTI BioPharma downgraded to Hold from Buy at WallachBeth - The Fly 11.09.15 | 07:11 am
- Piper reiterates Overweight on CTI BioPharma with $8 target - The Fly 11.02.15 | 06:11 am
- CTI BioPharma amendment shores up balance sheet in near-term, says Piper Jaffray - The Fly 06.10.15 | 02:06 pm
- CTI BioPharma shares should be bought on weakness, says Roth Capital - Fly On The Wall 03.16.15 | 09:03 am